Education > Webinar > Vanessa Stadlbauer-Köllner | The gut-liver axis as a novel therapeutic target in chronic liver disease

Vanessa Stadlbauer-Köllner | The gut-liver axis as a novel therapeutic target in chronic liver disease

Vanessa Stadlbauer-Köllner | The gut-liver axis as a novel therapeutic target in chronic liver disease

– Learn background information on the burden of chronic liver disease and on gut microbiome composition
– Understand the alterations in the gut-liver axis in chronic liver diseases
– Discover methods …


When
1st May 2019

This content is for verified practitioners only

Please create an account and login to view this educational resource.

Login / Register

Related Articles


Bio.Me, Microbiome
HMOs as Prebiotics to Reinforce Innate Immune System

Galactooligosaccharides (GOS) is one of our key supplements to promote a healthy microbiome for immune health and host-microbiome homeostasis.

Bio.Me, Bio.Me Barrier, Immunology & Inflammation, Microbiome
Probiotics and Immunity

The gut microbiota, probiotics and immunity for infectious diseases and immune health.

Bio.Me, Bio.Me Barrier, Gastrointestinal
Looking for a product to support gut barrier function?

When is barrier function a relevant clinical consideration? The importance of an effective physical and immune barrier at the site of host-microbiome interactions cannot be downplayed. Our solution is Bio....